Activity Overview
This online, on-demand virtual symposium brings together renowned experts in non–small cell lung cancer (NSCLC). In this educational program, expert thoracic pathologists and medical oncologists engage in concise didactic segments and case-based discussions to guide learners through real-world diagnostic, molecular, and therapeutic dilemmas across the NSCLC continuum. Faculty review best practices for optimizing tissue, implementing reflex testing, comparing tissue-based and plasma-based (liquid biopsy) workflows, and integrating novel therapeutics for emerging targets.
This educational activity is an archive of the live symposium held on March 25, 2026.
Target Audience
This educational activity is directed toward pathologists, as well as oncologists, advanced practice providers, oncology nurses, and other health care professionals involved in the multidisciplinary care of patients with NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Interpret tissue and liquid biopsy–based molecular testing results to support appropriate treatment selection for actionable mutations
- Evaluate emerging and established clinical trial data on targeted therapies in NSCLC
- Identify strategies to overcome barriers to biomarker testing and enhance collaboration between pathology and oncology teams for optimal patient care
Sanja Dacic, MD, PhD
Vice-Chair and Director of Anatomic Pathology
Department of Pathology
Yale School of Medicine
New Haven, CT
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca
Soo-Ryum (Stewart) Yang, MD
Assistant Attending Pathologist
Molecular Diagnostics and Thoracic Pathology
Co-Director, Clinical Biomarker Development
Early Drug Development Service (Solid Tumor)
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Amgen, AstraZeneca, Eli Lilly, Merus, Revolution Medicines, Roche, Sanofi
Isabel Preeshagul, DO, MBS
Thoracic Medical Oncologist
Memorial Sloan Kettering Bergen
Montvale, NJ
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, COR2ED GmbH, Dava Oncology, IDEOlogy Health, Johnson & Johnson, Medscape, Pfizer, Plexus Communications, Regeneron Pharmaceuticals, Takeda Pharmaceuticals
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here